The success of incretin mimetics – most notably Novo Nordisk Pharma AG’s Wegovy – in obesity is so extraordinary that large numbers of similarly acting agents are being pushed through clinical trials, their developers each hoping for a piece of the pie. What is perhaps less explicable is that other companies are pinning their hopes on obesity candidates with entirely different mechanisms.
Key Takeaways:
- A wide range of non-incretin strategies are being trialed in obesity
Incretins are peptide hormones that are secreted in the gut in response to a meal, stimulating pancreatic β-cells to secrete...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?